Payment overview · 2025
General Payments
$334.01
15 reported records · 3 companies
Healthcare provider profile · identity verified
John Patrick Card, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WINSTON SALEM, NC · NPI 1306826466
Verified facts
What the public records show
CMS Open Payments records show John Patrick Card, MD received $334.01 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 54.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $180.40 | 54.0% | 12 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $101.98 | 30.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.63 | 15.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.01 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $101.98 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.70 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.13 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.43 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 713 | 197 |
| Losartan Potassium | Losartan Potassium | 593 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 592 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 141 |
| Pravastatin Sodium | Pravastatin Sodium | 336 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 87 |
| Lisinopril | Lisinopril | 305 | 92 |
| Omeprazole | Omeprazole | 254 | 61 |
| Metformin Hcl Er | Metformin Hcl | 237 | 71 |
| Gabapentin | Gabapentin | 235 | 66 |
| Jardiance | Empagliflozin | 230 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 66 |
| Simvastatin | Simvastatin | 218 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 65 |
| Metformin Hcl | Metformin Hcl | 195 | 59 |
| Montelukast Sodium | Montelukast Sodium | 194 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 71 |
| Furosemide | Furosemide | 168 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 161 | 42 |
| Allopurinol | Allopurinol | 152 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 47 |
| Carvedilol | Carvedilol | 137 | 41 |
| Eliquis | Apixaban | 129 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 39 |
| Meloxicam | Meloxicam | 118 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 28 |
| Trazodone Hcl | Trazodone Hcl | 105 | 24 |
| Ozempic | Semaglutide | 102 | 18 |
| Glipizide Er | Glipizide | 97 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 29 |
| Potassium Chloride | Potassium Chloride | 94 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 33 |
| Ezetimibe | Ezetimibe | 82 | 23 |
| Buspirone Hcl | Buspirone Hcl | 80 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 14 |
| Atenolol | Atenolol | 72 | 20 |
| Glimepiride | Glimepiride | 71 | 21 |
| Alprazolam | Alprazolam | 70 | 14 |
| Sertraline Hcl | Sertraline Hcl | 67 | 20 |
| Famotidine | Famotidine | 65 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 19 |
| Bupropion Xl | Bupropion Hcl | 56 | 16 |
| Clonazepam | Clonazepam | 54 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Glipizide | Glipizide | 50 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 15 |
| Nystatin | Nystatin | 50 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 11 |
| Tramadol Hcl | Tramadol Hcl | 46 | 15 |
| Meclizine Hcl | Meclizine Hcl | 45 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 12 |
| Rybelsus | Semaglutide | 43 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 14 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Nabumetone | Nabumetone | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Colchicine | Colchicine | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 12 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 12 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.01 · 15 records | Novo Nordisk Inc | Dexcom G6 Transmitter, GIMOTI, Ozempic, Rybelsus, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error